Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

12
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
12
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

741
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
741
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Disorders of Hemostasis01:24

Disorders of Hemostasis

982
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
982
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

7
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
7
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

10
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Change of Cervical Cancer Stage at Diagnosis After the COVID-19 Pandemic.

Cureus·2026
Same author

Outpatient Delivery of Step-Up Doses to Rapidly Initiate Monthly Doses of Bispecific Antibodies in Multiple Myeloma.

European journal of haematology·2026
Same author

Tuberculosis reactivation in hematopoietic stem cell transplant recipients: a preemptive strategy in an endemic country.

Journal of clinical tuberculosis and other mycobacterial diseases·2025
Same author

Subgroup analysis of treatment pathways and clinical outcomes in Hodgkin lymphoma in Latin America from the retrospective B-HOLISTIC study.

Scientific reports·2025
Same author

Development of Polyvinyl Alcohol Hydrogels for Controlled Glucose Release in Biomedical Applications.

Gels (Basel, Switzerland)·2024
Same author

Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia.

Cancer causes & control : CCC·2024

Related Experiment Video

Updated: Jul 16, 2025

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

14.9K

Thrombotic events.

Gilberto Barranco-Lampón1,2, Raúl Martínez-Castro3, Luara Arana-Luna4

  • 1Servicio de Hematología, Hospital General de México, Ciudad de México, México.

Gaceta Medica De Mexico
|September 21, 2023
PubMed
Summary
This summary is machine-generated.

Thrombotic complications in myeloproliferative neoplasms (MPNs) are a significant clinical issue. Patients diagnosed with MPNs face a higher incidence of thrombosis, often arterial, with a substantial risk of recurrence.

Keywords:
AnticoagulaciónAnticoagulationMyeloproliferative NeoplasiaNeoplasia mieloproliferativaProfilaxisProphylaxisThrombosisTrombosis

More Related Videos

Ferric Chloride-Induced Arterial Thrombosis and Sample Collection for 3D Electron Microscopy Analysis
03:57

Ferric Chloride-Induced Arterial Thrombosis and Sample Collection for 3D Electron Microscopy Analysis

Published on: March 17, 2023

1.8K
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

2.8K

Related Experiment Videos

Last Updated: Jul 16, 2025

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

14.9K
Ferric Chloride-Induced Arterial Thrombosis and Sample Collection for 3D Electron Microscopy Analysis
03:57

Ferric Chloride-Induced Arterial Thrombosis and Sample Collection for 3D Electron Microscopy Analysis

Published on: March 17, 2023

1.8K
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

2.8K

Area of Science:

  • Hematology
  • Oncology
  • Vascular Medicine

Background:

  • Major thrombotic complications in myeloproliferative neoplasms (MPNs) present significant clinical challenges, contributing to high morbidity, complex management, and increased mortality.
  • Thrombosis occurrence in MPN patients indicates high thrombotic risk, necessitating cytoreductive treatment and secondary prophylaxis with antiplatelet or anticoagulant agents.
  • The incidence of thrombosis at diagnosis exceeds that during the disease course, with 60-70% occurring in the arterial territory.

Purpose of the Study:

  • To highlight the clinical significance of thrombotic complications in myeloproliferative neoplasms.
  • To underscore the implications of thrombosis for risk stratification and treatment initiation in MPN patients.
  • To review the incidence, location, and recurrence rates of thrombosis in MPN.

Main Methods:

  • Literature review of thrombotic complications in myeloproliferative neoplasms.
  • Analysis of incidence, location, and recurrence patterns of thrombosis in MPN patients.
  • Evaluation of the impact of thrombosis on clinical management and outcomes.

Main Results:

  • Thrombosis is a major complication of MPNs, associated with significant morbidity and mortality.
  • Arterial thrombosis accounts for the majority (60-70%) of thrombotic events at diagnosis.
  • A considerable proportion of patients (20-33%) experience recurrent thrombosis in the same vascular territory.

Conclusions:

  • Thrombotic events are critical indicators of high risk in MPN patients, guiding therapeutic decisions.
  • Secondary prophylaxis is crucial for managing the high risk of recurrence after an initial thrombotic event.
  • Understanding thrombosis patterns is essential for optimizing the care and improving outcomes for individuals with MPNs.